Next-Generation Delivery Technologies That Could Replace GLP-1 Injections | Research

The takeaway

This review maps the landscape of emerging GLP-1 delivery technologies — from oral pills and implantable pumps to cell therapies and smart devices — that aim to eliminate the need for weekly injections.

6 delivery platforms
The number of distinct technology categories reviewed as alternatives to current injectable GLP-1 receptor agonist delivery

What the researchers found

The review identifies several technology platforms poised to reshape GLP-1-based therapy delivery:

1. **Oral small-molecule agonists** — non-peptide compounds that activate GLP-1 receptors and can be taken as pills, avoiding injections entirely

2. **Ultralong-acting injectable technologies** — formulations designed to extend dosing intervals far beyond the current once-weekly standard

3. **Continuous-acting implantable pumps** — devices that deliver GLP-1 drugs steadily without patient intervention

4. **Smart-acting electronic devices** — technology-enabled delivery systems that can adjust dosing

5. **Nutrient-induced cell therapies** — engineered cells that produce GLP-1 in response to food intake, mimicking natural physiology

6. **Noninvasive delivery systems** — alternative routes that bypass needles entirely

Each approach addresses different patient needs and clinical challenges, from needle phobia to treatment adherence.

Why it matters

Hundreds of millions of people worldwide could benefit from GLP-1 therapies, but many are deterred by injectable administration, high costs, or the commitment to weekly dosing. The delivery technologies reviewed here could dramatically expand access by making treatment as simple as taking a daily pill, wearing a patch, or receiving a one-time implant. Solving the delivery challenge is arguably as important as the drug discovery itself for maximizing public health impact.

How the study worked

This is a comprehensive narrative review published in Endocrine Reviews. The authors surveyed the current clinical development pipeline and preclinical research landscape for GLP-1-based therapies, categorizing innovations by delivery technology type and assessing their current development stage, challenges, and potential for clinical translation.

What this study cannot tell us

As a review article, this paper synthesizes existing research rather than presenting new data. Many of the technologies discussed are in early preclinical stages and may not reach clinical use. The review may not capture all proprietary technologies under development by pharmaceutical companies. Real-world feasibility, cost comparisons, and patient preference data for these emerging approaches are largely unavailable.

How to read the evidence

This is an expert review article published in a top-tier endocrinology journal. It provides a comprehensive synthesis of the current development landscape but does not present original experimental data. The evidence level of individual technologies discussed ranges from preclinical to late-stage clinical trials.

When this study was published

Published in 2026, this is a cutting-edge review capturing the very latest developments in GLP-1 delivery technology. Given the rapid pace of innovation in this field, it represents the most current overview available.

The bigger picture

The GLP-1 drug revolution is entering its second phase. The first phase proved these drugs work extraordinarily well for diabetes, obesity, and potentially other conditions. The second phase — which this review maps — is about making them practical, affordable, and accessible for the billions of people who could benefit. The convergence of peptide science, materials engineering, electronic devices, and cell therapy represents a uniquely interdisciplinary approach to drug delivery.

Questions still open

Which delivery technology platform is closest to matching injectable semaglutide's efficacy in a non-injectable format?
How will the cost of these advanced delivery systems compare to current injectable formulations at scale?
Could combination approaches — such as smart devices with ultra-long-acting formulations — offer synergistic benefits for treatment adherence?

Common questions

Will GLP-1 drugs eventually be available as pills instead of injections?

Oral small-molecule GLP-1 receptor agonists are in active development and represent one of the most promising alternatives to injections. Unlike the current oral semaglutide (which is still a peptide requiring special absorption enhancers), these new molecules are non-peptide compounds designed specifically for oral bioavailability. Several are in clinical trials, though none have reached the market yet.

What are the main barriers to making GLP-1 drugs more accessible?

Three main challenges limit access: most require injections (which many patients avoid), they're expensive to manufacture as peptide drugs, and they need frequent dosing (typically weekly). The technologies reviewed in this paper aim to address all three — oral formulations eliminate needles, novel manufacturing could reduce costs, and ultra-long-acting approaches could extend dosing to monthly or beyond.

Read the original research

Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies.

Endocrine reviews, 47(1), 1-23

View on PubMed ↗Publisher’s paper ↗

Citation

Xu, Yining; Drucker, Daniel J; Traverso, Giovanni; Beloqui, Ana. (2026). Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies.. Endocrine reviews, 47(1), 1-23. https://doi.org/10.1210/endrev/bnaf027